BSE Live
Mar 11, 16:00Prev. Close
2.02
Open Price
2.02
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
2.02 (1876)
NSE Live
Mar 11, 15:32Prev. Close
1.75
Open Price
1.80
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Celestial Biolabs (in Rs. Cr.) | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 4.11 | 3.67 | 1.85 | 1.23 | 0.55 | |
| Net CashFlow From Operating Activities | 3.34 | 13.40 | 8.02 | 7.80 | 3.27 | |
| Net Cash Used In Investing Activities | -4.88 | -13.89 | -11.61 | -5.62 | -8.19 | |
| Net Cash Used From Financing Activities | 1.14 | -0.02 | 3.66 | -1.88 | 5.30 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -0.40 | -0.51 | 0.07 | 0.30 | 0.38 | |
| Cash And Cash Equivalents Begin of Year | 0.41 | 0.92 | 0.85 | 0.55 | 0.17 | |
| Cash And Cash Equivalents End Of Year | 0.01 | 0.41 | 0.92 | 0.85 | 0.55 |
19.03.2026
19.03.2026
18.03.2026
18.03.2026
MFs boost healthcare exposure, turn overweight on earnings recovery and valuations
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth